JD Capital-invested Well Lead Medical Listed on SSE


Well Lead Medical Co., Ltd. (Well Lead, 603309), invested by JD Capital, made its debut on the Shanghai Stock Exchange (SSE) on March 2, and closed the day with flying colors—up by 44.03% at 22.18 yuan per share.

Well Lead Medical, established in April 2004, specializes in the R&D, production, and sales of medical catheters for anaesthesia, urology, respiration and hemodialysis. Main products including trachea cannula, indwelling catheter, laryngeal mask and hemodialysis catheter are widely used in surgeries, therapy, emergency treatment and clinical care. Particularly, the production and sales of trachea cannula and indwelling catheter are well known both at home and abroad.

Fueled by market competition, Well Lead boasts strong synergies amongst various distribution channels, expanding its product scale, capacity and output to provide clients with one-stop purchasing. As for product quality, the company has a sound quality control system and sophisticated internal & management review procedures to ensure compliance with relevant regulatory requirements. In terms of product research, it has a R&D team comprising experienced experts from a wide range of fields such as clinical medicine, high polymer materials science, advanced manufacture, and production management in international medical equipment companies.

 They are well informed of the clinical demand, risk analysis, function definition, materials selection and modification, and manufacturing technique of medical catheters. As a domestic bellwether in medical catheters, Well Lead has obtained the ISO13485 certificate of quality system, nine registered products with the FDA (510K), 60 registered products with the European CE certification, as well as 75 domestic and 21 Canadian registration certificates for medical equipment products. For seven years in a row, Well Lead has been recognized as an annual “Category-A Enterprise of Quality Credit” by Guangdong Food and Drug Administration.

Well Lead has so far partnered with 100+ foreign medical equipment dealers and dozens of Chinese dealers and exporters. Its products are sold to over 70 countries and regions, and are used in more than 300 first-class hospitals in China alone.

Well Lead plans to issue 25 million shares at CNY 15.40 per share to raise CNY 378 million. It turns out that the company is widely recognized by secondary market investors. A total of 22.5 million shares, 90% of the total issuance, have been issued online and recorded a lot winning rate of 0.61%.

JD fund became a shareholder of Well Lead in 2011 and owned 8% of its shares prior to public issuance.